RESUMEN
OBJECTIVES: Alterations in dopamine neurotransmission underlie some of the clinical features of Huntington's disease (HD) and as such are a target for therapeutic intervention, especially for the treatment of chorea and some behavioural problems. However, justification for such an intervention is mainly based on case reports and small open label studies and the effects these drugs have on cognition in HD remain unclear. METHODS: In this study, we used the Enroll-HD observational database to assess the effects of antidopaminergic medication on motor, psychiatric and cognitive decline, over a 3-year period. We first looked at the annual rate of decline of a group of HD patients taking antidopaminergic medication (n=466) compared with an untreated matched group (n=466). The groups were matched on specified clinical variables using propensity score matching. Next, we studied a separate group of HD patients who were prescribed such medications part way through the study (n=90) and compared their rate of change before and after the drugs were introduced and compared this to a matched control group. RESULTS: We found that HD patients taking antidopaminergic medication had a slower progression in chorea and irritability compared with those not taking such medications. However, this same group of patients also displayed significantly greater rate of decline in a range of cognitive tasks. CONCLUSION: In conclusion we found that antidopaminergic treatment is associated with improvements in the choreic movements and irritability of HD but worsens cognition. However, further research is required to prospectively investigate this and whether these are causally linked, ideally in a double-blind placebo-controlled trial.
Asunto(s)
Corea/tratamiento farmacológico , Trastornos del Conocimiento/inducido químicamente , Cognición/efectos de los fármacos , Antagonistas de Dopamina/uso terapéutico , Enfermedad de Huntington/tratamiento farmacológico , Genio Irritable/efectos de los fármacos , Adulto , Anciano , Bases de Datos Factuales , Antagonistas de Dopamina/administración & dosificación , Antagonistas de Dopamina/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
OBJECTIVE: To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD). METHOD: Adults (N = 201) with treatment-resistant MDD or BD received repeat-dose IV ketamine treatment at a community-based clinic. Mixed features were measured using symptoms of anxiety, irritability, and agitation (AIA), as measured by the Generalized Anxiety Disorder-7 (GAD-7) scale. The Quick Inventory for Depressive Symptomatology Self-Report-16 (QIDS-SR16 ) was used to measure overall treatment response, and the QIDS-SR16 suicidal ideation (SI) item was used to measure change in SI symptoms with ketamine treatment. The anxiety, irritability, and agitation items on the GAD-7 were used to assess effectiveness of IV ketamine in treating symptoms of mixed features. RESULTS: In this retrospective analysis, 113 participants met AIA criteria. Participants with AIA experienced a significantly greater reduction in overall depressive symptoms (F(1, 558) = 9.49, P = .002), SI (F(1, 558) = 3.103, P = .079), anxiety (F(1, 198) = 5.52, P = .007), irritability (F(1, 198) = 28.35, P < .001), and agitation as measured by "trouble relaxing" (F(1, 198) = 6.70, P = .010) from baseline compared to the non-AIA group, regardless of number of treatments received. CONCLUSIONS: Our preliminary results suggest that IV ketamine is effective in rapidly treating AIA and SI in adults with treatment-resistant mood disorders. This observation suggests that IV ketamine could be considered a treatment alternative for adults with MDD or BD presenting with mixed features.
Asunto(s)
Ansiedad/tratamiento farmacológico , Trastorno Bipolar/tratamiento farmacológico , Trastorno Depresivo Mayor/tratamiento farmacológico , Genio Irritable/efectos de los fármacos , Ketamina/uso terapéutico , Agitación Psicomotora/tratamiento farmacológico , Adulto , Ansiedad/diagnóstico , Trastorno Bipolar/diagnóstico , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Resistente al Tratamiento/tratamiento farmacológico , Femenino , Humanos , Ketamina/administración & dosificación , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Autoinforme , Ideación SuicidaRESUMEN
BACKGROUND: Irritability is a adverse effect of many antiseizure medications (ASMs), but there are no validated measures currently available to characterize this behavioral risk. We examined both child and parent/guardian versions of the Affective Reactivity Index (ARI), a validated measure developed for application in adolescent psychiatry, to determine its sensitivity to ASM-related irritability. We hypothesized irritability increases associated with levetiracetam (LEV) but not lamotrigine (LTG) or oxcarbazepine (OXC). METHOD: The ARI was administered to 71 child and parent/guardian pairs randomized to one of three common ASMs (LEV, LTG, OXC) used to treat new-onset focal (localization-related) epilepsy. Subjects were recruited as part of a prospective multicenter, randomized, open-label, parallel group design. The ARI was administered at baseline prior to treatment initiation and again at 3â¯months after ASM initiation. RESULTS: There was a significant increase in ARI ratings for both child and parent/guardian ratings for LEV but not LTG or OXC when assessed 3â¯months after treatment initiation. When examined on the individual subject level using a criterion of at least a 3-point ARI increase, there was an increase associated with LEV for child ratings but not parent/guardian scores. CONCLUSION: Both child and parent/guardian versions of the ARI appear sensitive to medication-induced irritability associated with LEV on both the group and individual levels. The findings extend the applicability of ARI from characterizing the presence of clinical irritability as a psychiatric diagnostic feature to a more modifiable aspect of behavior change related to medication management and support its use in clinical trial applications.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Epilepsias Parciales/diagnóstico , Epilepsias Parciales/tratamiento farmacológico , Genio Irritable/efectos de los fármacos , Levetiracetam/uso terapéutico , Adolescente , Anticonvulsivantes/efectos adversos , Niño , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Genio Irritable/fisiología , Lamotrigina/efectos adversos , Lamotrigina/uso terapéutico , Levetiracetam/efectos adversos , Masculino , Oxcarbazepina/efectos adversos , Oxcarbazepina/uso terapéutico , Estudios ProspectivosRESUMEN
OBJECTIVES: The primary objective of the study was to analyze the efficacy of brivaracetam (BRV) in pediatric patients 12â¯months after starting treatment. The secondary objective was to establish safety 3, 6, and 12â¯months after starting treatment. MATERIALS AND METHOD: This was an observational and retrospective study. Data were collected from the electronic medical record. Inclusion criteria were as follows: patients under 18â¯years of age, diagnosis of focal or generalized epilepsy, treatment as an added therapy, initiation of treatment with BRV between June and September 2017, and at least one unprovoked seizure in the year prior to the start of treatment. RESULTS: Forty-six patients were included. The response rate was 65%, including 30% seizure-free patients. The rate of adverse effects was 43.5%, resulting in withdrawal in 16 patients (34.7%). The most common adverse effects were drowsiness (17.3%) and irritability (17.3%). CONCLUSIONS: Brivaracetam is effective in very diverse childhood epilepsies, including some that present with primarily generalized seizures. Given the characteristics of the population studied, we have not been able to confirm a better tolerability of BRV compared with levetiracetam (LEV).
Asunto(s)
Anticonvulsivantes/uso terapéutico , Epilepsias Parciales/diagnóstico , Epilepsias Parciales/tratamiento farmacológico , Epilepsia Generalizada/diagnóstico , Epilepsia Generalizada/tratamiento farmacológico , Pirrolidinonas/uso terapéutico , Adolescente , Anticonvulsivantes/efectos adversos , Niño , Femenino , Humanos , Genio Irritable/efectos de los fármacos , Genio Irritable/fisiología , Levetiracetam/efectos adversos , Levetiracetam/uso terapéutico , Masculino , Pirrolidinonas/efectos adversos , Estudios Retrospectivos , Resultado del Tratamiento , Vigilia/efectos de los fármacos , Vigilia/fisiologíaRESUMEN
OBJECTIVE: The objective of this study was to evaluate the efficacy and tolerability of perampanel (PER) in late adjunctive treatment of focal epilepsy. We assessed outcomes 1) according to patients' clinical profiles and the broad mechanism of action (MoA) of concomitant antiepileptic drugs (AEDs) and 2) the effects of PER on adverse events, irritability, mood, and quality of life (QOL). METHODS: Consecutive patients commenced on PER at two epilepsy centers in Melbourne, Australia were identified. A nested cohort underwent detailed prospective assessment, while the remainder were retrospectively analyzed. Six- and 12-month efficacy endpoints were at least a 50% reduction in seizure frequency (responders) and complete seizure freedom. The prospective cohort underwent standardized validated questionnaires at 0, 1, 3, 6, and 12â¯months using the modified semi-structured seizure interview (SSI), Liverpool Adverse Events Profile (LAEP), Quality of Life in Epilepsy-Patient-Weighted (QOLIE-10-P), Neurological Disorders Depression Inventory Epilepsy (NDDI-E), and an Irritability Questionnaire. RESULTS: One hundred sixty patients were followed for a median of 6â¯months: the mean number of prior AEDs was 6, 99% had drug-resistant epilepsy, and 72% had never experienced a prior seizure-free period of at least 6â¯months (=continuously refractory epilepsy). Perampanel was associated with responder and seizure freedom rates of 30.6% and 9.4% at 6â¯months and 19.4% and 4.4% (5.6% adjusted for the titration period) at 12â¯months. Having "continuously refractory epilepsy" was associated with a reduced likelihood of seizure freedom at 6â¯months (5% vs. 30%; pâ¯=â¯0.001) and 12â¯months (3% vs. 13%; pâ¯=â¯0.058). Quality of Life in Epilepsy-Patient-Weighted, irritability, and NDDI-E showed mean improvement at 6â¯months from baseline. SIGNIFICANCE: Even when used as late add-on adjunctive therapy in patients with highly refractory focal epilepsy, PER can result in 12-month seizure freedom of 5.6%. The likelihood of seizure freedom was associated with prior "continuous medication refractoriness". Six months after introduction of PER patients reported improved mood, QOL, and decreased irritability.
Asunto(s)
Anticonvulsivantes/administración & dosificación , Epilepsia Refractaria/tratamiento farmacológico , Epilepsia Refractaria/psicología , Genio Irritable/efectos de los fármacos , Piridonas/administración & dosificación , Calidad de Vida/psicología , Adulto , Afecto/efectos de los fármacos , Afecto/fisiología , Estudios de Cohortes , Quimioterapia Combinada , Femenino , Humanos , Genio Irritable/fisiología , Masculino , Persona de Mediana Edad , Nitrilos , Estudios Prospectivos , Estudios Retrospectivos , Convulsiones/tratamiento farmacológico , Convulsiones/psicología , Encuestas y Cuestionarios , Resultado del Tratamiento , Adulto JovenRESUMEN
WHAT IS KNOWN AND OBJECTIVE: The underlying pathophysiology of autism spectrum disorder (ASD) has been linked to immune dysregulation, oxidative stress and excitation-inhibition imbalance. Among associated symptoms of ASD, management of irritability has gained considerable attention as it complicates adjustment of ASD patients and thus necessitates its pharmacological treatment. Resveratrol is a plant phytoalexin, which has been demonstrated to have neuroprotective effects through its anti-inflammatory and antioxidant properties. This double-blind, placebo-controlled randomized trial was designed to assess the potential therapeutic effects of resveratrol plus risperidone on irritability of ASD patients. METHODS: Sixty-two patients were assigned randomly into two groups of resveratrol and placebo. Both groups were treated with risperidone twice daily starting at a dose of 0.5 mg with a dose increase of 0.5 mg per week (for the first 3 weeks). Resveratrol dosage was 250 mg twice per day from the beginning of the study. Using the Aberrant Behavior Checklist-Community (ABC-C), patients were assessed for ASD-related behavioural symptoms at baseline, week 5 and week 10. The frequency of adverse events was recorded using a checklist containing 25 possible side effects, including general, gastrointestinal, neurological and cardiovascular complications. RESULTS AND DISCUSSION: Improvements in primary outcome measure (irritability) and three secondary outcome measures (lethargy/social withdrawal, stereotypic behaviour and inappropriate speech subscales) in the resveratrol group were statistically similar to those in the placebo group. The repeated measures analysis showed no time × treatment interaction on these subscale scores. In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time × treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043). There was no significant difference in number and severity of adverse events between the two groups. WHAT IS NEW AND CONCLUSION: This clinical trial demonstrated no significant effect for adjunctive treatment with resveratrol on irritability of patients with ASD. However, it provided preliminary evidence indicating that resveratrol could improve hyperactivity/non-compliance of ASD patients.
Asunto(s)
Trastorno del Espectro Autista/tratamiento farmacológico , Genio Irritable/efectos de los fármacos , Resveratrol/administración & dosificación , Risperidona/administración & dosificación , Antipsicóticos/administración & dosificación , Trastorno del Espectro Autista/psicología , Niño , Preescolar , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Masculino , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/efectos adversos , Resveratrol/efectos adversos , Resultado del TratamientoRESUMEN
AIM: Irritability related to autism spectrum disorder (ASD) complicates the management of ASD patients at home and in clinical settings. In this randomized, double-blind, placebo-controlled clinical trial, we aimed to investigate the beneficial effects of adjuvant treatment with risperidone and sulforaphane in alleviating the irritability of children with ASD. METHODS: Sixty drug-free patients aged 4-12 years were randomly assigned to one of two groups receiving risperidone plus sulforaphane or placebo. Risperidone was started with a daily dose of 0.25 mg in patients weighing <20 kg and 0.5 mg in those weighing ≥20 kg and increased stepwise to reach a maximum of 1 mg (<20 kg), 2.5 mg (20-45 kg), and 3.5 mg (>45 kg). Sulforaphane was administered at a daily dose of 50 µmol (≤45 kg) or 100 µmol (>45 kg). The participants were assessed with the Aberrant Behavior Checklist - Community Edition at baseline and at Weeks 5 and 10. RESULTS: Compared to the placebo group, ASD patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008). However, no difference was seen in improvements in the other secondary measures: Lethargy/Social Interaction score, Stereotypic Behavior score, Inappropriate Speech score, and frequency of adverse events. CONCLUSION: Our results support the safety and efficacy of sulforaphane as an adjuvant to risperidone for improvement of irritability and hyperactivity symptoms in children with ASD.
Asunto(s)
Antiinflamatorios/farmacología , Antioxidantes/farmacología , Antipsicóticos/farmacología , Trastorno del Espectro Autista/tratamiento farmacológico , Trastorno del Espectro Autista/fisiopatología , Genio Irritable/efectos de los fármacos , Isotiocianatos/farmacología , Risperidona/farmacología , Sulfóxidos/farmacología , Antiinflamatorios/administración & dosificación , Antioxidantes/administración & dosificación , Antipsicóticos/administración & dosificación , Trastorno del Espectro Autista/inmunología , Trastorno del Espectro Autista/metabolismo , Niño , Preescolar , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Inflamación/tratamiento farmacológico , Isotiocianatos/administración & dosificación , Masculino , Estrés Oxidativo/efectos de los fármacos , Risperidona/administración & dosificación , Sulfóxidos/administración & dosificación , Resultado del TratamientoRESUMEN
Objectives: To systematically review literature on efficacy of amantadine on behavior (irritability/aggression/agitation, emotional lability, apathy, impairment of executive functioning), participation, quality-of-life (QoL), and safety, in patients with acquired brain injury (ABI). Amantadine is widely used clinically, so comprehensive information on efficacy, participation, QoL and safety is relevant. Methods: We used PRISMA Guidelines. We searched PubMed/EMBASE/CINAHL (last search 28-8-2018) Two independent reviewers performed selection and data-extraction. Quality of studies was assessed, using CONSORT and Quality Assessment Tool for Quantitative Studies (QATFQS). Results: Eleven out of 500 studies were included. Of five RCTs, two reported significant effects on irritability/aggression, and one no effect. One RCT on cognition no effect. One prospective cohort study showed a significant effect on executive functioning. One retrospective study was inconclusive. One single-case experimental design (SCED) study reported significant effect on apathy and three case-reports indicated effects on behavior. QoL and societal participation were not measured. No safety issues emerged. Conclusion: Amantadine may be efficacious on irritability and aggression after ABI. Amantadine is a safe drug in the presence of adequate creatinine clearance. Future studies should use designs, suitable for the heterogeneous ABI population, like randomized SCEDs, and should include the effect on societal participation and QoL.
Asunto(s)
Agresión/efectos de los fármacos , Amantadina/uso terapéutico , Lesiones Encefálicas/complicaciones , Disfunción Cognitiva/tratamiento farmacológico , Dopaminérgicos/uso terapéutico , Función Ejecutiva/efectos de los fármacos , Genio Irritable/efectos de los fármacos , Amantadina/administración & dosificación , Apatía/efectos de los fármacos , Disfunción Cognitiva/etiología , Dopaminérgicos/administración & dosificación , Humanos , Problema de Conducta , Calidad de Vida , Resultado del TratamientoRESUMEN
BACKGROUND: Many people with intellectual disabilities use risperidone long term for the management of challenging behaviours, despite its limited proof of effectiveness and its clear association with adverse events. Therefore, this study aimed to investigate the effectiveness of ongoing treatment with risperidone in reducing challenging behaviours versus controlled discontinuation on behaviour and health parameters. METHOD: This was a placebo-controlled, double-blind, randomised discontinuation trial of risperidone. In the discontinuation group, risperidone was gradually replaced by a placebo over 14 weeks, while the control group maintained their existing dosage. Eight weeks after discontinuation, behaviour (as measured by the 'Aberrant Behavior Checklist') and health parameters (dyskinesia, akathisia, parkinsonism, weight, waist circumference, sedation and laboratory outcomes) were compared in both groups. RESULTS: A total of 25 participants were included in the trial, of which 11 were randomised into the discontinuation group and 14 were randomised into the continued treatment group. In the discontinuation group, 82% completely withdrew from risperidone. There was no significant change in irritability, compared with the continuation group, although there was a Group*Time effects on stereotypical behaviour in favour of the continuation group. Significant Group*Time effects were also found for weight, waist, body mass index, prolactin levels and testosterone levels, with beneficial effects for the discontinuation group. CONCLUSION: Discontinuation of long-term risperidone for reducing challenging behaviours is possible, without an increase in irritability. Discontinuation of risperidone may have beneficial effects on weight, waist circumference, prolactin levels and testosterone levels. The study suffered from difficulties in achieving the required sample size, which affected study power and generalizability.
Asunto(s)
Antipsicóticos/administración & dosificación , Discapacidad Intelectual/tratamiento farmacológico , Genio Irritable/efectos de los fármacos , Evaluación de Resultado en la Atención de Salud , Problema de Conducta , Risperidona/administración & dosificación , Conducta Estereotipada/efectos de los fármacos , Adolescente , Adulto , Anciano , Niño , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
BACKGROUND: Activation is a behavioral adverse event related to the use of psychotropic medication. Its high incidence in pediatrics and in childhood-onset neuropsychiatric disorders suggests it may be linked to neurodevelopment. However, previous studies have scarcely examined the role that factors relevant to developmental pharmacokinetics, such as body weight, may play in the onset of activation in children and adolescents. METHODS: We conducted a retrospective analysis of hospitalized patients to identify the risk factors for activation in children and adolescents treated with selective serotonin reuptake inhibitors. Our focus was on factors related to development, including body weight, to explore the relationship between activation and neurodevelopmental processes. RESULTS: Among the 139 participants (mean age, 14 ± 2.3 years), activation appeared in 29 (20.9%). Age 12 years or younger and comorbid diagnosis of autism spectrum disorder were associated with statistically significant increases in the risk of activation, but no association was found regarding body weight. CONCLUSIONS: Our findings support the hypothesis that activation is closely linked to brain development processes. Longitudinal studies are needed to explore this line of research further.
Asunto(s)
Peso Corporal/fisiología , Trastornos del Neurodesarrollo/tratamiento farmacológico , Trastornos del Neurodesarrollo/psicología , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Adolescente , Acatisia Inducida por Medicamentos/metabolismo , Acatisia Inducida por Medicamentos/psicología , Peso Corporal/efectos de los fármacos , Niño , Femenino , Estudios de Seguimiento , Humanos , Genio Irritable/efectos de los fármacos , Genio Irritable/fisiología , Masculino , Trastornos del Neurodesarrollo/metabolismo , Estudios Retrospectivos , Factores de Riesgo , Conducta Autodestructiva/inducido químicamente , Conducta Autodestructiva/metabolismo , Conducta Autodestructiva/psicología , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Resultado del TratamientoRESUMEN
BACKGROUND: Few studies on adult and pediatric patients have shown pyridoxine efficacy as additional therapy for those receiving levetiracetam (LEV) to prevent and mitigate behavioral adverse effects (BAEs). OBJECTIVE: The aim of our study was to analyze the safety and efficacy of pyridoxine supplementation in the prevention of LEV adverse effects, including suicidal ideation. METHODS: This randomized, case-control trial included patients receiving LEV as monotherapy treatment. Patients were subdivided into 2 groups, according to whether they were treated with LEV only (group 1) or LEV with supplemental pyridoxine (group 2). RESULTS: In both cohorts, the most frequent BAEs were irritability/aggression followed by depression and confusion. Those patients (92%) who initiated pyridoxine after 1 month of LEV treatment did not need to change or suspend LEV ( P < 0.001), and BAE improved after 9.06 ± 3.05 days of pyridoxine supplementation. None of the patients complained of symptoms of pyridoxine toxicity, and no new adverse effects of LEV off-label were reported. CONCLUSIONS: In our study, we found pyridoxine to be safe and effective in controlling LEV-induced BAEs in children.
Asunto(s)
Anticonvulsivantes/efectos adversos , Conducta Infantil/efectos de los fármacos , Levetiracetam/efectos adversos , Piridoxina/administración & dosificación , Adolescente , Adulto , Agresión/efectos de los fármacos , Niño , Preescolar , Confusión/tratamiento farmacológico , Depresión/tratamiento farmacológico , Quimioterapia Combinada , Femenino , Humanos , Genio Irritable/efectos de los fármacos , Masculino , Resultado del TratamientoRESUMEN
Perampanel (PER) is a third generation antiepileptic drug (AED), recently approved as add-on therapy in both focal and generalized seizures. Levetiracetam (LEV) is a second generation AED, widely used in patients with epilepsy because of its favorable safety and efficacy profiles. Perampanel and LEV treatments have been associated with the occurrence of similar adverse events (AEs) (sleepiness, irritability, depression, anxiety, aggressiveness). The aim of the present retrospective single center study was to verify the efficacy and tolerability of PER and LEV used as first add-on therapy in patients with epilepsy affected by secondarily generalized seizures. We collected data from 15 patients treated with PER and 26 patients treated with LEV and followed at our site with follow-up visits at 3, 6, and 12months. This retrospective study documented the comparable efficacy of PER and LEV as first add-on treatments in patients affected by uncontrolled secondarily generalized seizures. However, more patients withdrawn LEV because of AEs compared with PER at the 3- and 12-month follow-up visits. The better tolerability of PER observed in this study could be related to the low therapeutic dose of PER prescribed when it is used as first adjunctive treatment for better controlling secondarily generalized seizures.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Epilepsia/tratamiento farmacológico , Levetiracetam/uso terapéutico , Piridonas/uso terapéutico , Convulsiones/tratamiento farmacológico , Adulto , Agresión , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/efectos adversos , Ansiedad , Depresión , Mareo/inducido químicamente , Epilepsia/epidemiología , Femenino , Humanos , Genio Irritable/efectos de los fármacos , Levetiracetam/administración & dosificación , Levetiracetam/efectos adversos , Masculino , Persona de Mediana Edad , Nitrilos , Piridonas/administración & dosificación , Piridonas/efectos adversos , Estudios Retrospectivos , Resultado del Tratamiento , VigiliaRESUMEN
Up to 25% of ovulating women suffer from primary dysmenorrhea, a condition associated with pain and transient-reduced quality of life, along with greater irritability and impaired sleep. In the present study, we asked whether and if so to what extent melatonin and meloxicam can improve subjective and objective sleep and reduce pain among women with primary dysmenorrhea (PD). To this end, we conducted a double-blind cross-over clinical trial lasting for three menstrual cycles. A total of 14 women (mean age M = 27.5 years) with primary dysmenorrhea took part in the study. At baseline, that is, during the first menstruation, they completed a visual analogue scale to rate pain; sleep continuity was assessed via actigraphs, and overall sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI). Next, participants were randomly assigned to one of two conditions, either melatonin during the second, and meloxicam during the third menstruation, or meloxicam during the second, and melatonin during the third menstruation. Neither participants nor investigators were aware of participants' study assignment. During the second and third menstruations, the assessments described above were repeated. At baseline, sleep assessed both objectively and subjectively was impaired, and pain was high. Subjective sleep improved and pain decreased during the second and third menstruations irrespective of whether melatonin or meloxicam was administered first or second. Likewise, objective sleep efficiency increased and objective sleep latency shortened. The efficacy of melatonin was superior to that of meloxicam. The present pattern of results suggests that both melatonin and meloxicam are suitable to treat pain and PD-related sleep complaints among women with primary dysmenorrhea.
Asunto(s)
Dismenorrea , Melatonina/administración & dosificación , Meloxicam/administración & dosificación , Dolor , Calidad de Vida , Trastornos del Sueño-Vigilia , Adulto , Antioxidantes/administración & dosificación , Estudios Cruzados , Inhibidores de la Ciclooxigenasa 2/administración & dosificación , Método Doble Ciego , Dismenorrea/complicaciones , Dismenorrea/diagnóstico , Dismenorrea/psicología , Femenino , Humanos , Genio Irritable/efectos de los fármacos , Dolor/diagnóstico , Dolor/tratamiento farmacológico , Dolor/etiología , Proyectos Piloto , Trastornos del Sueño-Vigilia/etiología , Trastornos del Sueño-Vigilia/fisiopatología , Trastornos del Sueño-Vigilia/terapia , Resultado del Tratamiento , Escala Visual AnalógicaRESUMEN
AIM: The purpose of this study was to evaluate the long-term safety and efficacy of aripiprazole in treating irritability in pediatric patients (6-17 years) with autistic disorder (AD) in Japan. METHODS: In this open-label extension study, patients who had completed a previous randomized, double-blind, placebo-controlled 8-week study were enrolled and were flexibly dosed with aripiprazole (1-15 mg/day) until the new indication of irritability in pediatric autism spectrum disorder was approved in Japan. RESULTS: Seventy (81%) out of 86 enrolled patients completed week-48 assessments. The mean duration of treatment was 694.9 days. The mean daily dose of aripiprazole over the treatment period was 7.2 mg and the mean of the final dose was 8.5 mg. The most common treatment-emergent adverse events (TEAE; ≥20%) included nasopharyngitis, somnolence, influenza, and increased weight. The majority of these TEAE were mild or moderate in severity, and there were no deaths, and no clinically relevant findings in laboratory values except prolactin decrease, vital signs, height, or ECG parameters. At week 48 (observed case), the mean change from baseline in the Irritability subscale score for the Aberrant Behavior Checklist Japanese Version was -6.3 in prior placebo patients and -2.6 in prior aripiprazole patients. CONCLUSION: Aripiprazole was generally safe, well tolerated, and effective in the long-term treatment of irritability associated with AD in Japanese pediatric patients.
Asunto(s)
Antipsicóticos/farmacología , Aripiprazol/farmacología , Trastorno del Espectro Autista/tratamiento farmacológico , Genio Irritable/efectos de los fármacos , Evaluación de Resultado en la Atención de Salud , Adolescente , Antipsicóticos/efectos adversos , Aripiprazol/efectos adversos , Trastorno del Espectro Autista/fisiopatología , Niño , Femenino , Humanos , Japón , MasculinoRESUMEN
BACKGROUND: Impairment of cognitive function as well as negative symptom is the major factor causing the decline of a patient's functioning in chronic stages of schizophrenia. However, until now, there were no definite treatment options that could effectively reduce the impairment. CASE PRESENTATION: We report a case of mood dysregulation associated with use of Ginkgo biloba in a patient with schizophrenia. After Ginkgo biloba was given, the patient experienced cluster symptoms of mood dysregulation including irritability, difficulty in controlling anger, agitation and restlessness. We estimated the possibility as "probable" according to Naranjo scale considering circumstantial evidence. CONCLUSIONS: This case suggests that Ginkgo biloba may have caused mood dysregulation in this patient. Although it is generally accepted as safe, more attention should be given to the adverse effect when treating with Ginkgo biloba.
Asunto(s)
Trastornos del Humor/inducido químicamente , Trastornos del Humor/complicaciones , Extractos Vegetales/efectos adversos , Esquizofrenia/complicaciones , Femenino , Ginkgo biloba , Humanos , Genio Irritable/efectos de los fármacos , Persona de Mediana EdadRESUMEN
Although montelukast is generally well tolerated, postmarketing studies have reported serious neuropsychiatric adverse drug reactions (ADRs) leading to a United States Food and Drug Administration black box warning. The objective of this study was to determine the incidence of neuropsychiatric ADRs leading to discontinuation of montelukast in asthmatic children.We conducted a retrospective cohort study in children aged 1-17â years initiated on montelukast. In a nested cohort study, children initiated on montelukast as monotherapy or adjunct therapy to inhaled corticosteroids (ICS) were matched to those initiated on ICS monotherapy. A non-leading parental interview served to ascertain the occurrence of any ADRs with any asthma medication, and circumstances related to, and evolution of, the event.Out of the 106 participants who initiated montelukast, most were male (58%), Caucasian (62%) with a median (interquartile range) age of 5 (3-8)â years. The incidence (95% CI) of drug cessation due to neuropsychiatric ADRs was 16 (10-26)%, mostly occurring within 2â weeks. Most frequent ADRs were irritability, aggressiveness and sleep disturbances. The relative risk of neuropsychiatric ADRs associated with montelukast versus ICS was 12 (2-90).In the real-life setting, asthmatic children initiated on montelukast experienced a notable risk of neuropsychiatric ADRs leading to drug cessation, that is significantly higher than that associated with ICS.
Asunto(s)
Acetatos , Agresión/efectos de los fármacos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Glucocorticoides , Genio Irritable/efectos de los fármacos , Quinolinas , Trastornos del Sueño-Vigilia/inducido químicamente , Acetatos/administración & dosificación , Acetatos/efectos adversos , Adolescente , Antiasmáticos/administración & dosificación , Antiasmáticos/efectos adversos , Asma/diagnóstico , Asma/tratamiento farmacológico , Asma/epidemiología , Canadá/epidemiología , Preescolar , Ciclopropanos , Quimioterapia Combinada/métodos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Humanos , Lactante , Masculino , Pruebas Neuropsicológicas , Vigilancia de Productos Comercializados , Quinolinas/administración & dosificación , Quinolinas/efectos adversos , Estudios Retrospectivos , Sulfuros , Privación de Tratamiento/estadística & datos numéricosRESUMEN
PURPOSE: The objective of this work was to review systematically the efficacy and tolerability of perampanel (PER) in residential patients of an epilepsy center. METHOD: We adopted an industry-independent noninterventional retrospective evaluation on the basis of the paper and electronic records complemented by personal information on the part of the treating neurologists. All patients (N=26, 15 females, mean age: 30, range 21-55years) started on PER from its introduction to the market in September 2012 until December 15th 2013 were included. Evaluation was carried out after 6, 12, and 24months of PER treatment. Changes in seizure frequency were calculated as the number of seizures during three months on PER compared to a three-month baseline period. The Clinical Global Impression Scale served as an instrument to record changes in seizure intensity beyond numerical values. Adverse effects were documented by means of the Liverpool Adverse Events Profile. RESULTS: Most patients had structural or metabolic epilepsy, 2 patients suffered from Lennox-Gastaut syndrome, 2 from other symptomatic generalized epilepsy. All patients had grade III drug-resistant epilepsy. All patients had additional cognitive deficits of different degree. The retention rates were 61.5% after 6months, 46.2% after 12months, and 42.3% after 24months. The responder rates were 11.5% after 6months, 23.1% after 12months, and 7.7% after 24months. Partial responders (positive CGI and/or seizure reduction <50%) included, the respective values were 26.9%, 38.5%, and 23.1%. Only 1 patient was seizure free at 12months (but not at 24months). A loss of efficacy in the second year of treatment was suspected but the decrease of the responder rate could also be ascribed to a number of different circumstances. Adverse effects in the psychiatric field like irritability, aggression, increased sensitivity, and suicidal ideation/behavior occurred in 50% of the patients. They were the main reason to discontinue PER. CONCLUSIONS: After one year of treatment PER showed reasonable efficacy in a particularly difficult-to-treat population. Psychiatric adverse effects forced discontinuation in many cases.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Disfunción Cognitiva/tratamiento farmacológico , Disfunción Cognitiva/psicología , Epilepsia Refractaria/tratamiento farmacológico , Epilepsia Refractaria/psicología , Piridonas/uso terapéutico , Adulto , Agresión/efectos de los fármacos , Anticonvulsivantes/efectos adversos , Disfunción Cognitiva/diagnóstico , Epilepsia Refractaria/diagnóstico , Femenino , Humanos , Genio Irritable/efectos de los fármacos , Masculino , Persona de Mediana Edad , Nitrilos , Piridonas/efectos adversos , Estudios Retrospectivos , Ideación Suicida , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVE: The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating major depressive disorder (MDD) with mixed features including irritability. METHODS: The data in this analysis were derived from a study of patients meeting DSM-IV-TR criteria for unipolar MDD, with a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26, presenting with two or three protocol-defined manic symptoms, and who were randomized to 6 weeks of double-blind treatment with either lurasidone 20-60 mg/d (n=109) or placebo (n=100). We defined "irritability" as a score ≥2 on both the Young Mania Rating Scale (YMRS) irritability item (#5) and the disruptive-aggressive item (#9). Endpoint change in the MADRS and YMRS items 5 and 9 were analyzed using a mixed model for repeated measures for patients with and without irritability. RESULTS: Some 20.7% of patients met the criteria for irritability. Treatment with lurasidone was associated with a significant week 6 change vs. placebo in MADRS score in both patients with (-22.6 vs. -9.5, p<0.0001, effect size [ES]=1.4) and without (-19.9 vs. -13.8, p<0.0001, ES=0.7) irritability. In patients with irritable features, treatment with lurasidone was associated with significant week 6 changes vs. placebo in both the YMRS irritability item (-1.4 vs. -0.3, p=0.0012, ES=1.0) and the YMRS disruptive-aggressive item (-1.0 vs. -0.3, p=0.0002, ES=1.2). CONCLUSIONS: In our post-hoc analysis of a randomized, placebo-controlled, 6-week trial, treatment with lurasidone significantly improved depressive symptoms in MDD patients with mixed features including irritability. In addition, irritability symptoms significantly improved in patients treated with lurasidone.
Asunto(s)
Trastorno Bipolar/tratamiento farmacológico , Trastorno Depresivo Mayor/tratamiento farmacológico , Genio Irritable/efectos de los fármacos , Clorhidrato de Lurasidona/uso terapéutico , Adulto , Trastorno Bipolar/diagnóstico , Trastorno Bipolar/psicología , Comorbilidad , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/psicología , Femenino , Humanos , Clorhidrato de Lurasidona/efectos adversos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
OBJECTIVES: This study assessed the effects of oral porcine placental extract (PPE) on the mild menopausal symptoms of climacteric women. METHODS: In this 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, 50 climacteric Japanese women were randomized 1 : 1 to oral PPE (300 mg/day) or placebo. Menopausal symptoms were evaluated by using the Simplified Menopausal Index (SMI), as were serum estradiol (E2) and follicle stimulating hormone (FSH) levels. Blood biochemical and cellular and urinary tests were done to evaluate safety aspects of repeated oral administration of PPE. RESULTS: The total SMI score of the PPE group was significantly more improved after 12 weeks than that of the placebo group (p = 0.031). This score and three subscores (vasomotor, psychological, and somatic symptoms) were significantly improved at 8 and/or 12 weeks compared with the initial values in the PPE group (p < 0.05). E2 and FSH levels were not improved in either group. No adverse events were observed. CONCLUSIONS: Oral PPE at 300 mg/day improved the mild menopausal symptoms of climacteric women. Since oral PPE did not improve serum E2 and FSH levels, PPE is thought not to ameliorate hormonal balance itself but to improve subjective feelings of climacteric women.
Asunto(s)
Menopausia/efectos de los fármacos , Extractos Placentarios/administración & dosificación , Administración Oral , Animales , Depresión/tratamiento farmacológico , Método Doble Ciego , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Sofocos/tratamiento farmacológico , Humanos , Genio Irritable/efectos de los fármacos , Japón , Menopausia/sangre , Persona de Mediana Edad , Encuestas y Cuestionarios , Porcinos , Evaluación de Síntomas/métodos , Resultado del TratamientoRESUMEN
OBJECTIVE: To assess the effects of amantadine on anger and aggression among individuals with a chronic traumatic brain injury (TBI). METHODS: A cohort of 118 persons with chronic TBI (>6 months postinjury) and moderate-severe aggression selected from a larger cohort of 168 participants enrolled in a parallel-group, randomized, double-blind, placebo-controlled trial of amantadine 100 mg twice daily (n = 82) versus placebo (n = 86) for treatment of irritability were studied. Anger and aggression were measured at treatment days 0, 28, and 60 using observer-rated and participant-rated State-Trait Anger Expression Inventory-2 (STAXI-2) and Neuropsychiatric Inventory-Agitation/Aggression domain (NPI-A) Most Problematic and Distress scores. RESULTS: Participant-rated day 60 NPI-A Most Problematic (adjusted P = .0118) and NPI-A Distress (adjusted P = .0118) were statistically significant between the 2 groups, but STAXI-2 differences were not significant after adjustment for multiple comparisons. Substantial improvements were noted in both amantadine and placebo groups (70% vs 56% improving at least 3 points on day 60 Observer NPI-A; P = .11). CONCLUSION: Amantadine 100 mg twice daily in this population with chronic TBI appears to be beneficial in decreasing aggression from the perspective of the individual with TBI. No beneficial impact on anger was found. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00779324; http://www.clinicaltrials.gov/ct2/show/NCT00779324?term=irritability&rank=6.